The 87-year history of heparin began in 1916 when a 26-year-old medical student named Jay McLean startled his mentor William Howell, Professor of Physiology at Johns Hopkins University, by proclaiming that he had discovered “antithrombin.” This discovery was so surprising to Howell because he had expected McLean to isolate thromboplastin, a clot-promoting substance from animal tissue. In 1928, Charles Best, M.D., in Toronto, Canada, organized a team of chemists, physiologists, and surgeons to focus on the development of heparin. This group determined which animal tissues were the best source, had performed purification and identification, and had determined pharmacologic properties in vitro. By 1935, they were ready for human trials. By 1941, the group reported a series of 700 patients treated with the glycosaminoglycan called heparin. Meanwhile a critical cofactor, antithrombin, had been discovered at the University of Iowa (Brinkhous, et al). Introduction of newer tests for laboratory monitoring enabled refinement of dosages during the 1960s and 1970s. Its use permitted the development of hemodialysis and cardiopulmonary bypass surgery, and the prophylaxis of deep vein thrombosis in surgical patients. The concept of low-molecular-weight heparin occurred to Dr. Choay and others in France in the late 1970s. During the 1980s and 1990s, the development of low-molecular-weight heparins evolved for both prophylaxis and therapy. The first synthetic product was called the pentasaccharide, named for the five critical sugar units in heparin that bind to antithrombin (1983). Since then, this drug has been studied extensively to prove its clinical efficacy and safety.
KEYWORDS
Heparin - antithrombin - history - low-molecular-weight heparin - pentasaccharide
REFERENCES
-
1 Messmore H, Wehrmacher W, Jeske W. From Heparin to Pentasaccharide. Oral Presentation at the Annual Meeting of the International Union of Angiology New York, NY; March, 2002
-
2
McLean J.
The thromboplastic action of heparin.
Am J Physiol.
1916;
41
250-257
-
3
Jaques L.
Addendum: the discovery of heparin.
Semin Thromb Hemost.
1978;
4
350-353
-
4
McLean J.
The discovery of heparin.
Circulation.
1959;
19
75-78
-
5
Howell W H, Holt E.
Two new factors in blood coagulation-heparin and pro-antithrombin.
Am J Physiol.
1918;
17
328-341
-
6
Howell W H.
Heparin an anticoagulant.
Am J Physiol.
1922-1923;
63
434-435
-
7
Howell W H.
The purification of heparin and its chemical and physiologic reactions.
Johns Hopkins Hosp Med J.
1928;
42
199-205
-
8
Best C H.
Preparation of heparin and its use in the first clinical cases.
Circulation.
1959;
19
79-86
-
9
Lam C.
The strange story of Jay McLean, the discoverer of heparin.
Henry Ford Hosp Med J.
1985;
33
18-23
-
10 Bigelow H G. Mysterious Heparin. The Key to Open Heart Surgery. Toronto; McGaw-Hill Ryerson 1990
-
11 Roden L. Highlights in the history of heparin. In: Lane D, Lindahl U Heparin. Chemical and Biological Properties, Clinical Applications. London; Edward Arnold 1989: 1-23
-
12
Best C H.
Heparin and thrombosis.
Harvey Lect.
1941;
36
66-70
-
13
Charles A F, Scott D A.
Preparation of heparin from beef lung.
Trans Roy Soc Canada.
1934;
28
, sect V.55
-
14
Scott D A, Charles A F.
Studies on heparin III. The purification of heparin.
J Biol Chem.
1933;
102
437-448
-
15
Charles A F, Scott D A.
Studies on heparin II. Heparin in various tissues.
J Biol Chem.
1933;
102
431-435
-
16
Charles A F, Scott IV D A.
Observations on the chemistry of heparin.
Biochem J.
1936;
30
1927-1933
-
17
Scott D, Charles A.
Studies on heparin. I. The preparation of heparin.
J Biol Chem.
1933;
102
425-436
-
18
Best C H.
Heparin and vascular occlusion.
Can Med Assoc J.
1936;
35
621-622
-
19
Jaques L R, Waters E T.
The isolation of crystalline heparin from the blood of dogs in anaphylactic shock.
Am J Physiol.
1940;
129
389-390
-
20
Jacques L.
Heparinase.
J Biol Chem.
1940;
133
445-451
-
21
Murray G, Delorme E, Thomas N.
Development of an artificial kidney and clinical experiences.
Arch Surg.
1947;
55
505-522
-
22
Murray G, Best C.
Heparin and thrombosis.
JAMA.
1940;
110
118-119
-
23
Jorpes S.
The chemistry of heparin.
Biochem J.
1935;
29
1817-1830
-
24
Jorpes S.
Heparin: a mucopolysaccharide and an active antithrombotic drug.
Circulation.
1959;
19
87-96
-
25
Holmgren H, Wilander O.
Beitrag zur Kenntnis der Chemie und Funktion der Ehrlichsen Mastzellen.
Zeitschr mikroscopisch anatomische Forschung.
1937;
42
242-245
-
26 Nader H B, Dietrich C P. Natural occurrence and possible biological role of heparin. In: Lane DA, Lindahl U Heparin. London; Edward Arnold 1989: 81-113
-
27
Bauer G.
Clinical experiences of a surgeon in the use of heparin.
Am J Cardiol.
1964;
14
29-35
-
28 Wright I. The use of heparin as an antithrombotic agent-a panel discussion. In: Bradshaw R, Wessler S Heparin. Structure, Function and Clinical Implications. New York; Plenum Press 1975: 389-409
-
29
Lam C.
The neutralization of heparin by protamine.
Surgery.
1948;
2
197-199
-
30 Barrowcliffe T. Heparin assays and standardization. In: Lane DA, Lindahl U Heparin. London; Edward Arnold 1989: 393-415
-
31
Hyers T, Agnelli G, Hull R et al..
Antithrombotic therapy for venous thromboembolic disease.
Chest.
2001;
110
176S-193S
-
32
Basu D, Gallus A, Hirsh J, Cade J.
A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.
N Engl J Med.
1972;
287
324-327
-
33
Anand S, Ginsberg J S, Kearon C et al..
The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
Arch Intern Med.
1996;
156
1677-1681
-
34
Yin E T, Wessler S, Butler J V.
Plasma heparin: a unique, practical submicrogram-sensitive assay.
J Lab Clin Med.
1973;
81
298-310
-
35
Yin E T.
Appraisal of clot based and amidolytic anti-Xa methods for the monitoring of heparin and its derivatives.
Semin Thromb Hemost.
1985;
11
243-244
-
36
Holmer E.
A new single chromogenic substrate assay for heparin-like anti-FXa activity in plasma.
Thromb Haemost.
1985;
54
(abst 29)
-
37
Brinkhous K, Smith H, Warner E, Seegers W.
The inhibition of blood clotting. An unidentified substance that acts in conjunction with heparin to prevent prothrombin conversion.
Am J Physiol.
1939;
125
683-687
-
38
Levine M N, Hirsch J, Gent M et al..
A randomized trial comparing partial thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Arch Intern Med.
1994;
154
49-56
-
39
Young E, Prins H M, Levine M N et al..
Heparin binding to plasma proteins:an important mechanism for heparin resistance.
Thromb Haemost.
1992;
67
639-643
-
40
Rosenberg R D, Lam L.
Correlation between structure and function of heparin.
Proc Natl Acad Sci USA.
1979;
76
1218-1222
-
41
Yin E T, Wessler S.
Heparin accelerated inhibition of factor X by its natural plasma inhibitor.
Biochim Biophys Acta.
1970;
201
387-390
-
42
Kakkar V V, Spindler J, Corrigan T et al..
Efficacy of low doses of heparin in preventing deep vein thrombosis after major surgery.
Lancet.
1972;
2
101-106
-
43
Sagar S.
Efficacy of low dose heparin in prevention of extensive deep vein thrombosis in patients undergoing total hip replacement.
Lancet.
1976;
1
1151-1156
-
44
Wehrmacher W, Karlman R, Scanlon P, Messmore H.
Anticoagulant therapy of thromboembolic disease during pregnancy.
Compr Ther.
1998;
24
289-294
-
45
Messmore H.
Heparin induced thrombocytopenia: historical review.
Clin Appl Thromb Hemost.
1999;
5(suppl 1)
82-86
-
46 Warkentin T. History of heparin induced thrombocytopenia. In: Warkentin T, Greinacher A Heparin Induced Thrombocytopenia. New York; Marcel Dekker 2001: 1-18
-
47 Warkentin T. Heparin induced thrombocytopenia. In: Kitchens C, Alving B, Kessler C Consultative Hemostasis and Thrombosis. Philadelphia, PA; Elsevier Science 2002: 355-372
-
48
Lam H, Silbert J, Rosenberg R P.
The separation of active and inactive forms of heparin.
Biochem Biophys Res Commun.
1976;
69
570-577
-
49
Anderson L O, Barrowcliffe T W, Holmer E, Johnson E A, Sims G EC.
Anticoagulant properties of heparin fractionated by affinity chromatography on matrix bound antithrombin and by gel filtration.
Thromb Res.
1976;
9
545-583
-
50
Hook M, Bjork J, Hopwood J, Lindahl U.
Anticoagulant activity of heparin species by affinity chromatography on immobilized antithrombin.
FEBS Lett.
1976;
66
90-93
-
51 Willaime P, Choay J. A heparin story: from serendipity to rationality. 10th Anniversary International Symposium on Advances in Anticoagulant, Antithrombotic and Thrombolytic Drugs (AATD), the IBC Meeting, Boston, MA, October 1999
-
52
Seegers W H, Marciniak E.
Inhibition of autoprothrombin C activity with plasma.
Nature.
1962;
193
1188-1190
-
53
Barlow G.
Molecular weight distribution determinations on heparin samples.
Thromb Res.
1983;
31
513-519
-
54
Graham D, Pomeroy A.
Relative activities of heparin fractions obtained by gel chromatography.
Thromb Haemost.
1979;
42
1598-1603
-
55
Aiach M, Michaud A, Balian J-L, Lefevore M, Woler M, Fourtillan J.
A new low molecular weight heparin derivative.
Thromb Res.
1983;
31
611-621
-
56
Holmer E, Karachi K, Soderstrom G.
The molecular weight dependence of the rate enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin.
Biochem J.
1981;
193
395-400
-
57
Weitz J L.
Low molecular weight heparins.
N Engl J Med.
1997;
337
688-698
-
58
Jordan R E, Oosta G, Gardner W T.
The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin.
J Biol Chem.
1980;
255
10081-10090
-
59
Carter C J, Kelton J, Hirsh J, Cerskua A, Santos A.
The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits.
Blood.
1982;
59
1239-1245
-
60
Holmer E, Soderberg K.
Inhibition of heparin oligosaccharides by protamine chloride.
Semin Thromb Hemost.
1985;
11
241-242
-
61
Palm M, Mattsen C.
Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal and metabolic clearance.
Thromb Haemost.
1987;
58
932-935
-
62
Racanelli A, Fareed J, Walenga J M.
Biochemical and pharmacological studies on protamine interactions with heparin, its fractions and fragments.
Semin Thromb Hemost.
1985;
11
176-189
-
63
Bratt G, Tornebohm L, Widlund L et al..
Low molecular weight heparin (Kabi 2165 Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers.
Thromb Res.
1986;
42
613-620
-
64
Warkentin T E, Levine M N, Hirsh J et al..
Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin.
N Engl J Med.
1995;
332
1330-1335
-
65
Kakkar V V, Djazeri B, Fok J, Fletcher M, Scully M F, Westwick J.
Low molecular weight heparins prevention of postoperative deep vein thrombosis.
BMJ.
1982;
284
375-379
-
66
Turpie A GG, Levine M, Hirsh J, Carter C, Jay M, Powers P J.
A randomized controlled trial of low molecular weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery.
N Engl J Med.
1986;
315
925-929
-
67
LeClerc J, Geerts W, Desjardins L.
Prevention of VTE after knee arthroplasty: A randomized double blind trial comparing enoxaparin with warfarin.
Ann Intern Med.
1996;
124
619-626
-
68
Knudsen M M, Morabito D, Parement G, Shackleford S.
Use of low molecular weight heparin in preventing thromboembolism in trauma patients.
J Trauma.
1996;
41
446-459
-
69
Litin S, Heit J, Mees K.
Use of low molecular weight heparin in the treatment of venous thromboembolic disease. Answers to frequently asked questions.
Mayo Clin Proc.
1998;
73
545-551
-
70
Samama M M.
Contemporary laboratory monitoring of low molecular weight heparins.
J Clin Lab Med.
1995;
15
119-123
-
71
Rabah M, Premmereur J, Graham M et al..
Usefulness of intravenous enoxaparin for percutaneous coronary intervention or unstable angina pectoris.
Am J Cardiol.
1999;
84
1391-1395
-
72
Koza M, Messmore H, Wallock M, Walenga J, Pifarre R.
Evaluation of a low molecular weight heparins with standard heparin for hemodialysis in dogs.
Blood.
1984;
64(suppl 1)
238a
-
73
Ibbotson T, Goa K.
Enoxaparin. An update of its clinical use in the management of acute coronary syndromes.
Drugs.
2002;
62
1407-1431
-
74
Lee A YY, Levine M N, Baker R I et al..
Low molecular weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
N Engl J Med.
2003;
349
146-153
-
75
Zacharsky L R.
Malignancy as a solid phase coagulopathy: implications for the etiology, pathogenesis and treatment of cancer.
Semin Thromb Hemost.
2003;
29
239-246
-
76
Kwaan H C, Parmar S, Wang J.
Pathogenesis of increased risk of thrombosis in cancer.
Semin Thromb Hemost.
2003;
29
283-288
-
77
Valentine K A, Hull R D, Pineo G F.
Low molecular weight heparin therapy and mortality.
Semin Thromb Hemost.
1997;
23
173-178
-
78
Bick R L.
Cancer associated thrombosis.
N Engl J Med.
2003;
349
109-111
-
79
Lee A YY, Levine M N, Baker R et al..
Low molecular weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
N Engl J Med.
2003;
349
146-153
-
80
Messmore H, Jeske W, Wehrmacher W, Walenga J.
Benefit risk assessment of treatment for heparin-induced thrombocytopenia.
Drug Saf.
2003;
26
625-641
-
81
Walenga J, Jeske W, Samama M, Frapaise F, Bick R L, Fareed J.
Fondaparinux: A synthetic heparin pentasaccharide as a new antithrombotic agent.
Expert Opin Investig Drugs.
2002;
11
1-11
-
82
Keam S, Goa K.
Fondaparinux sodium.
Drugs.
2002;
62
1673-1685
-
83
Eriksson B I, Bauer K A, Lassen M R, Turpie A GG.
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
N Engl J Med.
2001;
345
1298-1304
-
84
Bauer K A, Eriksson B I, Lassen M R, Turpie A GG.
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
N Engl J Med.
2001;
345
1305-1310
Harry L Messmore JrM.D.
Cancer Center, Loyola University Medical Center
2160 S. First Avenue
Maywood, IL 60153
eMail: hlmehd64@aol.com
